Manufacturer with High Purity and Competitive Price
Commercial Supply Darifenacin Hydrobromide Related Intermediates:
(S)-3-Hydroxypyrrolidine Hydrochloride CAS: 122536-94-1
(S)-α,α-Diphenyl-3-Pyrrolidineacetamide L-Tartrate CAS: 134002-26-9
(S)-2,2-Diphenyl-2-(Pyrrolidin-3-yl)acetonitrile Hydrobromide CAS: 194602-27-2
(S)-2,2-Diphenyl-2-(1-Tosylpyrrolidin-3-yl)acetonitrile CAS: 133099-09-9
2,3-Dihydrobenzofuran CAS: 496-16-2
2,3-Dihydrobenzofuranyl-5-Acetic Acid CAS: 69999-16-2
5-(2-Bromoethyl)-2,3-Dihydrobenzofuran CAS: 127264-14-6
Darifenacin Hydrobromide CAS: 133099-07-7
| Chemical Name |
(S)-3-Hydroxypyrrolidine Hydrochloride |
| Synonyms |
(S)-3-Hydroxypyrrolidine HCl; (S)-3-Pyrrolidinol Hydrochloride; (S)-Pyrrolidin-3-ol (Hydrochloride); (S)-Pyrrolidin-3-ol, HCl |
| CAS Number |
122536-94-1 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C4H10ClNO |
| Molecular Weight |
123.581 |
| Melting Point |
104.0~107.0℃ |
| Boiling Point |
108.0~110.0℃ (8mmHg) |
| Solubility |
DMSO (Sparingly), Methanol (Slightly) |
| Stability |
Hygroscopic |
| Shipping Condition |
Shipped Under Ambient Temperature |
| COA & MSDS |
Available |
| Place of Origin |
Shanghai, China |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
Results |
| Appearance |
Off-White to Brown Crystalline Powder |
Pale Brown Crystalline Powder |
| Chemical Purity |
≥98.0% (GC) |
99.6% |
| Specific Optical Rotation |
+6.5° ~ +8.5° (C=3 CH3OH) |
7.6° |
| Melting Point |
104.0~107.0℃ |
106.0~107.0℃ |
| Any Individual Impurity |
≤0.50% |
Conforms |
| Total Impurities |
≤2.00% |
Conforms |
| Loss on Drying |
≤0.50% |
Conforms |
| Infrared Spectrometry |
Conforms to Structure |
Conforms |
| Conclusion |
The product has been tested and complies with the given specifications |
| Usage |
Intermediate of Darifenacin Hydrobromide (CAS: 133099-07-7) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Hazard Symbols Xi - Irritant
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S37 - Wear suitable gloves.
HS Code 2933990099
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-3-Hydroxypyrrolidine Hydrochloride (CAS: 122536-94-1) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and Active Pharmaceutical Ingredient (API) synthesis. (S)-3-Hydroxypyrrolidine Hydrochloride (CAS: 122536-94-1) is the main intermediate of Darifenacin Hydrobromide (CAS: 133099-07-7).
Darifenacin Hydrobromide (CAS: 133099-07-7), an orally active, once a day selective M3 receptor antagonist, was launched for the treatment of overactive bladder in patients with symptoms of urge urinary incontinence, urgency and frequency. The drug selectively inhibits M3 receptor in the detrusor muscle while sparing the M1 and M2 receptors that are believed to be involved in central nervous system and cardiovascular function respectively. The compound was originally developed by Pfizer and licensed to Novartis and Bayer.